NIOX Group (LON:NIOX) Trading 3.8% Higher - Here's Why

Key Points

• NIOX Group shares increased by 3.8% on Wednesday, trading at GBX 72.23 ($0.98) after closing at GBX 69.60 ($0.94).
• The company, with a market capitalization of £29.67 billion, has a high price-to-earnings ratio of 2,980.72 and insider ownership of 46.72%.
• NIOX Group focuses on non-invasive diagnostic products for chronic respiratory diseases, improving management of conditions like asthma and COPD.

NIOX Group Plc (LON:NIOX - ) shares shot up 3.8% on Wednesday . The company traded as high as GBX 73 ($0.99) and last traded at GBX 72.23 ($0.98). 852,805 shares changed hands during trading, a decline of 22% from the average session volume of 1,094,688 shares. The stock had previously closed at GBX 69.60 ($0.94).

NIOX Group Trading Up 3.8%

The firm has a market capitalization of £29.67 billion, a price-to-earnings ratio of 2,980.72 and a beta of 0.92. The business's 50-day simple moving average is GBX 68.72 and its two-hundred day simple moving average is GBX 66.70. The company has a quick ratio of 1.94, a current ratio of 6.31 and a debt-to-equity ratio of 1.10.

Insider Buying and Selling at NIOX Group

In related news, insider Ian Johnson purchased 144,844 shares of the company's stock in a transaction on Wednesday, June 25th. The stock was acquired at an average cost of GBX 8 per share, for a total transaction of £11,587.52. 46.72% of the stock is currently owned by corporate insiders.

NIOX Group Company Profile

NIOX Group plc is a medical technology company focused on improving the lives of millions of people suffering from respiratory health issues globally. NIOX develops and markets innovative, non-invasive diagnostic products for chronic airway diseases, primarily asthma and COPD. Its lead product, NIOX VERO®, enables the accurate measurement of fractional exhaled nitric oxide (FeNO), an established biomarker for airway inflammation, supporting better diagnosis, monitoring and management of asthma and COPD in clinical and research settings. Headquartered in the UK and listed on the London Stock Exchange ticker: NIOX, the company operates internationally, serving healthcare professionals in over 50 countries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.